Overview
This report analyzes the current and future scenario of the global dementia associated with Alzheimer’s disease market for the period 2019 to 2026. Rise in geriatric population, increased prevalence of Alzheimer’s, high unmet medical needs, and rich pipeline are likely to be major drivers of the global dementia associated with Alzheimer’s disease market during the forecast period.
The dementia associated with Alzheimer’s disease market report comprises an elaborate executive summary, including a snapshot that provides information on various segments of the market. It also provides information and data analysis of the global market with respect to segments based on drug class, distribution channel, and region. A detailed qualitative analysis of drivers, restraints, and opportunities of the market has been provided in the market overview section. Additionally, the section comprises competitive matrix and profiles of key market players, along with business overview, to project the competitive landscape of the market. The section also provides market attractiveness analysis based on region and market share analysis in terms of key players, thereby presenting a thorough analysis of the overall competitive scenario in the dementia associated with Alzheimer’s disease market.
Dementia Associated with Alzheimer’s Disease Market: Key Segments
Based on drug class, the global dementia associated with Alzheimer’s disease market has been segmented into cholinergic/ cholinesterase (ChE) inhibitors, memantine, and combined drug (memantine & donepezil) and others. The segments have been analyzed based on available drugs used during the treatment of AD and cost-effectiveness. In terms of distribution channel, the global dementia associated with Alzheimer’s disease market has been divided into hospital pharmacies, retail, and online sales. Based on market size and forecast for each of these segments have been provided for the period 2019 to 2026, along with their respective CAGR for the forecast period 2016 to 2026, considering 2018 as the base year.
Dementia Associated with Alzheimer’s Disease Market: Regional Outlook
In terms of region, the global dementia associated with Alzheimer’s disease market has been segmented into five major regions: North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, and Rest of Middle East & Africa). Market size and forecast for each of these regions and the mentioned countries have been provided for the period 2019 to 2026, along with their respective CAGR for the forecast period 2016 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.
Companies Mentioned in the Report
The report also profiles major players operating in the global dementia associated with Alzheimer’s disease market based on various attributes, such as company overview, financial overview, product portfolio, business strategies, and recent developments. The players covered in the report include Merz Pharma GmbH & Co. KGaA., Novartis AG, Allergan plc. Pfizer, Inc., Daiichi Sankyo Company, Limited, Ono Pharmaceutical Co., Ltd, Johnson & Johnson Services, Inc., Eisai Co., Ltd., H. Lundbeck A/S, and F. Hoffmann-La Roche Ltd.
Report Segmentation
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Dementia Associated with Alzheimer's Disease Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Class Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Dementia Associated with Alzheimer's Disease Market Analysis and Forecast, 2018–2026
4.4.1. Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Projections
4.5. Porter’s Five Force Analysis
5. Market Outlook
5.1. Disease Prevalence & Incidence Rate Globally with Key Countries
5.2. Pipeline Analysis
6. Global Dementia Associated with Alzheimer's disease Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Dementia Associated with Alzheimer's disease Market Value Forecast, by Drug Class, 2018–2026
6.3.1. Cholinergic/ Cholinesterase (ChE) Inhibitors
6.3.1.1. Donepezil
6.3.1.2. Galantamine
6.3.1.3. Rivastigmine
6.3.2. Memantine
6.3.3. Combined Drug (Memantine & Donepezil) and Others
6.4. Global Dementia Associated with Alzheimer's disease Market Attractiveness, by Drug Class
7. Global Dementia Associated with Alzheimer's disease Market Analysis and Forecast, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Dementia Associated with Alzheimer's Disease Market Value Forecast, by Distribution Channel, 2018–2026
7.3.1. Hospital Pharmacies
7.3.2. Retail
7.3.3. Online Sales
7.4. Global Dementia Associated with Alzheimer's Disease Market Attractiveness, by Distribution Channel
8. Global Dementia Associated with Alzheimer's Disease Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Global Dementia Associated with Alzheimer's Disease Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Global Dementia Associated with Alzheimer's Disease Market Attractiveness, by Country/Region
9. North America Dementia Associated with Alzheimer's Disease Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. North America Dementia Associated with Alzheimer's Disease Market Value Forecast, by Drug Class, 2018–2026
9.2.1. Cholinergic/ Cholinesterase (ChE) Inhibitors
9.2.1.1. Donepezil
9.2.1.2. Galantamine
9.2.1.3. Rivastigmine
9.2.2. Memantine
9.2.3. Combined Drug (Memantine & Donepezil) and Others
9.3. North America Dementia Associated with Alzheimer's Disease Market Value Forecast, by Distribution Channel, 2018–2026
9.3.1. Hospital Pharmacies
9.3.2. Retail
9.3.3. Online Sales
9.4. North America Dementia Associated with Alzheimer's Disease Market Value Forecast, by Country, 2018–2026
9.4.1. U.S.
9.4.2. Canada
9.5. North America Dementia Associated with Alzheimer's Disease Market Attractiveness Analysis
9.5.1. By Drug Class
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Dementia Associated with Alzheimer's Disease Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Europe Dementia Associated with Alzheimer's Disease Market Value Forecast, by Drug Class, 2018–2026
10.2.1. Cholinergic/ Cholinesterase (ChE) Inhibitors
10.2.1.1. Donepezil
10.2.1.2. Galantamine
10.2.1.3. Rivastigmine
10.2.2. Memantine
10.2.3. Combined Drug (Memantine & Donepezil) and Others
10.3. Europe Dementia Associated with Alzheimer's Disease Market Value Forecast, by Distribution Channel, 2018–2026
10.3.1. Hospital Pharmacies
10.3.2. Retail
10.3.3. Online Sales
10.4. Europe Dementia Associated with Alzheimer's Disease Market Value Forecast, by Country/Sub-region, 2018–2026
10.4.1. Germany
10.4.2. France
10.4.3. U.K.
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Europe Dementia Associated with Alzheimer's Disease Market Attractiveness Analysis
10.5.1. By Drug Class
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region
11. Asia Pacific Dementia Associated with Alzheimer's Disease Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Asia Pacific Dementia Associated with Alzheimer's Disease Market Value Forecast, by Drug Class, 2018–2026
11.2.1. Cholinergic/ Cholinesterase (ChE) Inhibitors
11.2.1.1. Donepezil
11.2.1.2. Galantamine
11.2.1.3. Rivastigmine
11.2.2. Memantine
11.2.3. Combined Drug (Memantine & Donepezil) and Others
11.3. Asia Pacific Dementia Associated with Alzheimer's Disease Market Value Forecast, by Distribution Channel, 2018–2026
11.3.1. Hospital Pharmacies
11.3.2. Retail
11.3.3. Online Sales
11.4. Asia Pacific Dementia Associated with Alzheimer's Disease Market Value Forecast, by Country/Sub-region, 2018–2026
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Asia Pacific Dementia Associated with Alzheimer's Disease Market Attractiveness Analysis
11.5.1. By Drug Class
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region
12. Latin America Dementia Associated with Alzheimer's Disease Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Latin America Dementia Associated with Alzheimer's Disease Market Value Forecast, by Drug Class, 2018–2026
12.2.1. Cholinergic/ Cholinesterase (ChE) Inhibitors
12.2.1.1. Donepezil
12.2.1.2. Galantamine
12.2.1.3. Rivastigmine
12.2.2. Memantine
12.2.3. Combined Drug (Memantine &Donepezil) and Others
12.3. Latin America Dementia Associated with Alzheimer's Disease Market Value Forecast, by Distribution Channel, 2018–2026
12.3.1. Hospital Pharmacies
12.3.2. Retail
12.3.3. Online Sales
12.4. Latin America Dementia Associated with Alzheimer's Disease Market Value Forecast, by Country/Sub-region, 2018–2026
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Dementia Associated with Alzheimer's Disease Market Attractiveness Analysis
12.5.1. By Drug Class
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region
13. Middle East & Africa Dementia Associated with Alzheimer's Disease Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Middle East & Africa Dementia Associated with Alzheimer's Disease Market Value Forecast, by Drug Class, 2018–2026
13.2.1. Cholinergic/ Cholinesterase (ChE) Inhibitors
13.2.1.1. Donepezil
13.2.1.2. Galantamine
13.2.1.3. Rivastigmine
13.2.2. Memantine
13.2.3. Combined Drug (Memantine & Donepezil) and Others
13.3. Middle East & Africa Dementia Associated with Alzheimer's Disease Market Value Forecast, by Distribution Channel, 2018–2026
13.3.1. Hospital Pharmacies
13.3.2. Retail
13.3.3. Online Sales
13.4. Middle East & Africa Dementia Associated with Alzheimer's Disease Market Value Forecast, by Country/Sub-region, 2018–2026
13.4.1. GCC Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. Middle East & Africa Dementia Associated with Alzheimer's Disease Market Attractiveness Analysis
13.5.1. By Drug Class
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of companies)
14.2. Market Share Analysis by Company (2018)
14.3. Market Footprint Analysis
14.3.1. By Region
14.3.2. By Drug Class Type
14.4. Competitive Business Strategies
14.5. Company Profiles
14.5.1. Merz Pharma GmbH & Co. KGaA
14.5.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.1.2. Product Portfolio
14.5.1.3. SWOT Analysis
14.5.1.4. Financial Overview
14.5.1.5. Strategic Overview
14.5.2. Novartis AG
14.5.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.2.2. Product Portfolio
14.5.2.3. SWOT Analysis
14.5.2.4. Financial Overview
14.5.2.5. Strategic Overview
14.5.3. Allergan plc.
14.5.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.3.2. Product Portfolio
14.5.3.3. SWOT Analysis
14.5.3.4. Financial Overview
14.5.3.5. Strategic Overview
14.5.4. Pfizer, Inc.
14.5.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.4.2. Product Portfolio
14.5.4.3. SWOT Analysis
14.5.4.4. Financial Overview
14.5.4.5. Strategic Overview
14.5.5. Daiichi Sankyo Company, Limited
14.5.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.5.2. Product Portfolio
14.5.5.3. SWOT Analysis
14.5.5.4. Financial Overview
14.5.5.5. Strategic Overview
14.5.6. Ono Pharmaceutical Co., Ltd.
14.5.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.6.2. Product Portfolio
14.5.6.3. SWOT Analysis
14.5.6.4. Financial Overview
14.5.6.5. Strategic Overview
14.5.7. Johnson & Johnson Services, Inc.
14.5.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.7.2. Product Portfolio
14.5.7.3. SWOT Analysis
14.5.7.4. Financial Overview
14.5.7.5. Strategic Overview
14.5.8. Eisai Co., Ltd.
14.5.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.8.2. Product Portfolio
14.5.8.3. SWOT Analysis
14.5.8.4. Financial Overview
14.5.8.5. Strategic Overview
14.5.9. H. Lundbeck A/S
14.5.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.9.2. Product Portfolio
14.5.9.3. SWOT Analysis
14.5.9.4. Financial Overview
14.5.9.5. Strategic Overview
14.5.10. F. Hoffmann-La Roche Ltd.
14.5.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.10.2. Product Portfolio
14.5.10.3. SWOT Analysis
14.5.10.4. Financial Overview
14.5.10.5. Strategic Overvie
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers